"After a preliminary safety review, subsequent patients will then be randomized to 350 or 700 mg of weekly leronlimab with the same background regimen. The Data and Safety Monitoring Board (DSMB) will perform a second safety review after the first 20 patients have completed at least 1 cycle of therapy. The DSMB can then recommend restricting further enrollment to a single dose level, should they identify a signal of superior activity in either one of the treatment arms."

https://www.cytodyn.com/newsroom/press-releas...areholders

more detail of the first 5 patients in the March 18, 2025 press release
" the first five patients enrolled will receive 350 mg of leronlimab SQ once/week in combination with TAS-102 and bevacizumab. After a preliminary safety review by the Data and Safety Monitoring Board (“DSMB”), subsequent patients will be randomized to 350 or 700 mg of weekly leronlimab along with the same background regimen. The DSMB will perform a second safety review after the first 20 patients have completed at least 1 cycle of therapy and can then recommend restricting further enrollment to a single dose level, if deemed appropriate. "
https://www.cytodyn.com/newsroom/press-releas...areholders


CFO also said on 10/21/25
https://ldmicrocasts.com/#register
(video: Day 2, Track 4) "So we are expecting to have between 15 and 20 patients enrolled in the study by year end. That's important because we're looking at the PD-L1 increase, and we'll have that hopefully in the first quarter of 2026 to be able to report that out."